Cargando…

Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients

The measurement of serum neurofilament light chain (sNfL) is of growing importance in the field of neurology. In the management of multiple sclerosis, it can serve as a useful marker to assess disease activity and treatment response. This paper compares two available methods, namely the Single Molec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nötzel, Martin, Werder, Luise Ina, Ziemssen, Tjalf, Akgün, Katja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604350/ https://www.ncbi.nlm.nih.gov/pubmed/36293227 http://dx.doi.org/10.3390/ijms232012361

Ejemplares similares

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis
por: Gauthier, Audrey, et al.
Publicado: (2021)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study
por: Truffi, Marta, et al.
Publicado: (2023)

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021)

Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS
por: Akgün, Katja, et al.
Publicado: (2019)

Molecular biomarkers in multiple sclerosis
por: Ziemssen, Tjalf, et al.
Publicado: (2019)

Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies
por: Saak, Annika, et al.
Publicado: (2021)

Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children
por: Nitz, Elisa, et al.
Publicado: (2021)

Acute Effects of Ocrelizumab Infusion in Multiple Sclerosis Patients
por: Akgün, Katja, et al.
Publicado: (2022)

The need for a strategic therapeutic approach: multiple sclerosis in check
por: Inojosa, Hernan, et al.
Publicado: (2022)

Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis
por: Woopen, Christina, et al.
Publicado: (2021)

Digital Twins for Multiple Sclerosis
por: Voigt, Isabel, et al.
Publicado: (2021)

Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects
por: Fischer, Stefanie, et al.
Publicado: (2021)

Digital Biomarkers in Multiple Sclerosis
por: Dillenseger, Anja, et al.
Publicado: (2021)

S1P receptor modulators and the cardiovascular autonomic nervous system in multiple sclerosis: a narrative review
por: Constantinescu, Victor, et al.
Publicado: (2022)

Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis
por: Akgün, Katja, et al.
Publicado: (2018)

Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis
por: Akgün, Katja, et al.
Publicado: (2020)

Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies
por: Akgün, Katja, et al.
Publicado: (2019)

Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses
por: Woopen, Christina, et al.
Publicado: (2022)

Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not
por: Frank, Anika, et al.
Publicado: (2022)

Serum neurofilament light chain and initial severity of neurological disease predict the early neurological deterioration in Wilson’s disease
por: Ziemssen, Tjalf, et al.
Publicado: (2022)

Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up
por: Kaufmann, Maxi, et al.
Publicado: (2018)

Can ChatGPT explain it? Use of artificial intelligence in multiple sclerosis communication
por: Inojosa, Hernan, et al.
Publicado: (2023)

Influence of exercise on quantity and deformability of immune cells in multiple sclerosis
por: Proschmann, Undine, et al.
Publicado: (2023)

No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis
por: Inojosa, Hernan, et al.
Publicado: (2020)

The potential of serum neurofilament as biomarker for multiple sclerosis
por: Bittner, Stefan, et al.
Publicado: (2021)

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
por: Ziemssen, Tjalf, et al.
Publicado: (2016)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
por: Calabresi, Peter A, et al.
Publicado: (2020)

Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world
por: Ziemssen, Tjalf, et al.
Publicado: (2017)

Digital Innovation in Multiple Sclerosis Management
por: Ziemssen, Tjalf, et al.
Publicado: (2021)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
por: Li, Kai, et al.
Publicado: (2017)

CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study
por: Häusler, Darius, et al.
Publicado: (2021)

Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System
por: Kern, Raimar, et al.
Publicado: (2016)

Timing of SARS-CoV-2 Vaccination Matters in People With Multiple Sclerosis on Pulsed Anti-CD20 Treatment
por: Woopen, Christina, et al.
Publicado: (2022)

Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting
por: Rodriguez-Leal, Francisco Alejandro, et al.
Publicado: (2019)

Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis
por: Jin, Mengmeng, et al.
Publicado: (2020)

Serum neurofilament light as a biomarker in progressive multiple sclerosis
por: Kapoor, Raju, et al.
Publicado: (2020)

Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis
por: Galetta, Kristin, et al.
Publicado: (2021)

Association of serum neurofilament light with microglial activation in multiple sclerosis
por: Saraste, Maija, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s4i0ek8heir88ofccufdi76aso